What should be done for cirrhotic ascites and splenomegaly?

Aug 10, 2022 Source: Cainiu Health
Dr. Zhao Haiming
Introduction
For patients with cirrhosis-associated ascites and splenomegaly, conservative management should be the initial approach, followed by antifibrotic therapy. Surgical intervention may also be considered; however, if the condition is not severe, conventional (non-surgical) treatment may suffice—thereby effectively enhancing the body’s immune resistance. Additionally, splenectomy or splenic artery embolization may be considered in cases of hypersplenism caused by splenic congestion, which commonly manifests as thrombocytopenia, leukopenia, and an increased risk of bleeding.

  Splenomegaly alone generally cannot be defined as cirrhosis. Some cases of splenomegaly are not caused by cirrhosis; however, as the disease progresses, some patients with hepatitis often develop cirrhosis. Secondary portal hypertension, splenomegaly, and hypersplenism constitute the most common clinical causes. So, what should be done for patients with cirrhosis who present with ascites and splenomegaly?

  Management of Cirrhosis with Ascites and Splenomegaly

  For cirrhosis-associated ascites and splenomegaly, conservative treatment should be initiated first, followed by antifibrotic therapy. Surgical intervention may also be considered; however, if the condition is not severe, general supportive treatment may suffice—this approach can effectively enhance the body’s resistance. Alternatively, splenectomy or splenic artery embolization may be considered when hypersplenism—manifesting clinically as thrombocytopenia, leukopenia, and increased bleeding tendency—is attributable to splenic congestion. Generally, if splenomegaly is not accompanied by severe thrombocytopenia or leukopenia, hepatic compensatory function remains adequate, and surgical intervention or splenic embolization should preferably be avoided.

  However, if no hypersplenic manifestations are present, clinical intervention may still be warranted. To a certain extent, most patients with cirrhosis and splenomegaly require close monitoring, as this condition predisposes them to infection or hemorrhage, potentially triggering more serious clinical complications. If splenomegaly results from cirrhosis, there is no need for excessive concern—standard medical management should be initiated first, followed by selection of an appropriate therapeutic strategy.

  In daily life, patients should adhere to a regulated diet—avoiding spicy, irritating foods and refraining from binge eating or staying up late. We hope this information proves helpful.